top menu action banner

PAZONIX (PAZOPANIB) 400MG Tablets 60`S

Ksh 73,499

In Stock

  • Product Categories:

WHAT IS THIS MEDICINE AND WHAT IS IT USED FOR?

Pazonix contains pazopanib, a targeted cancer medicine that blocks several proteins (called receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT) that cancer cells and nearby blood vessels use to grow and form new blood vessels.

Without a blood supply, tumours cannot get the nutrients they need to grow and spread.

Pazopanib is used in adults for: advanced renal cell carcinoma (kidney cancer) — as a first-line treatment or after previous immunotherapy; and advanced soft tissue sarcoma (a type of cancer affecting muscles, fat, tendons, and other connective tissues) — in patients who have had prior chemotherapy.

The 400mg tablet is more convenient for patients on the standard 800mg daily dose — instead of taking four 200mg tablets, they take two 400mg tablets.

 

3. HOW TO TAKE THIS MEDICINE

Standard dose: two 400mg tablets once daily (800mg total), taken on an empty stomach — at least 1 hour before or 2 hours after eating. If a dose reduction is required (to 600mg or 400mg), the 200mg tablet will likely be prescribed instead for greater flexibility. Swallow whole with water. Do not crush or break. Take at the same time each day.

 

The 400mg tablet is primarily a convenience formulation for patients stable on the standard 800mg dose.

 

PATIENT TIP: Taking two tablets instead of four is a practical improvement in your daily routine — but all the safety monitoring and precautions remain exactly the same. Continue daily blood pressure checks, attend all liver function appointments, and report any new symptoms as described for the 200mg tablet.

 

4. POSSIBLE SIDE EFFECTS

POSSIBLE SIDE EFFECTS

How Common?

Side Effects

Very Common

High blood pressure (hypertension — very common, affecting most patients), diarrhoea, hair colour changes (depigmentation — hair may turn lighter or grey-white), nausea, fatigue, decreased appetite, vomiting, weight loss, raised liver enzymes on blood tests

Common

Headache, taste changes (metallic or reduced taste), skin problems (rash, hand-foot syndrome — redness and soreness on palms and soles), hypothyroidism (underactive thyroid), raised blood sugar

Serious — Tell Your Doctor Right Away

Liver toxicity (hepatotoxicity): jaundice (yellow skin or eyes), dark urine, right-sided tummy pain — can be severe and occasionally fatal; requires urgent review and possible treatment discontinuation. Severe high blood pressure or hypertensive crisis. Arterial thromboembolism (heart attack, stroke — sudden chest pain, weakness, speech difficulty). Tumour-related bleeding. QT prolongation (heart rhythm change). Gastrointestinal perforation or fistula (severe abdominal pain).

 

5. WHO SHOULD NOT TAKE THIS MEDICINE

Pazopanib should not be used during pregnancy — it can seriously harm an unborn baby. Effective contraception is essential during treatment and for at least 2 weeks after the last dose.

It must be used with extreme caution — or avoided — in patients with significant liver impairment (it is primarily processed by the liver). Do not use in patients with a recent history of heart attack, stroke, or serious haemorrhage.

 

LIVER TOXICITY: This is the most serious safety concern with pazopanib. Liver enzyme tests (ALT, AST) must be checked before treatment, then at weeks 3, 5, 7, and 9, then monthly for the first year. Liver failure has occurred. Report any jaundice, dark urine, or severe fatigue immediately.

BLOOD PRESSURE MONITORING: Monitor blood pressure daily at home and keep a log. High blood pressure must be treated promptly — it increases the risk of stroke and heart attack. If BP exceeds 150/100 mmHg, contact your care team.

EMPTY STOMACH: Always take pazopanib on an empty stomach. A high-fat meal increases absorption dramatically and can cause unpredictable and dangerous drug levels.

 

6. MEDICINES THAT INTERACT WITH THIS TREATMENT

Strong CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit juice, clarithromycin) significantly raise pazopanib levels — avoid these. Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St. John's Wort) reduce efficacy — avoid.

Pazopanib itself inhibits CYP enzymes and may raise levels of statins (particularly simvastatin) and other CYP substrates — discuss all medicines with your oncologist. QT-prolonging medicines increase cardiac risk. Proton pump inhibitors (omeprazole) reduce pazopanib absorption — avoid or take pazopanib at a specific time relative to the PPI.

 

7. HOW TO STORE THIS MEDICINE

Store below 25°C in original packaging. Keep away from moisture and light. Keep out of reach of children.

 

8. PRESCRIPTION REQUIREMENT

Field

Details

Status

Prescription Only Medicine (POM) — Specialist (oncology) prescription required

 

9. GUIDANCE FOR PATIENTS & CAREGIVERS

Take your tablets on an empty stomach — at least 1 hour before eating or 2 hours after a meal — at the same time each day. Check your blood pressure every day and keep a written log to share with your oncology team.

Attend all liver function blood test appointments without fail. Report any yellow discolouration of skin or eyes, dark urine, or severe right-sided tummy pain to your oncologist immediately.

Protect your hands and feet with thick moisturiser to manage hand-foot syndrome. Avoid grapefruit. Use effective contraception throughout treatment.

 

10. PHARMACIST & PRESCRIBER NOTES

Field

Details

Clinical Dispensing Notes

Fasting administration is critical — food (especially high-fat meal) dramatically increases AUC. LFT monitoring schedule: pre-treatment, weeks 3, 5, 7, 9, then monthly for 12 months — hepatotoxicity is the primary safety concern and can be fatal. BP monitoring: daily home monitoring, treat hypertension promptly. CYP3A4 interaction screening mandatory — avoid strong inhibitors and inducers. Grapefruit counselling. PPI interaction: advise separation or switch to short-acting H2 blocker taken in morning. Statin interaction (especially simvastatin, atorvastatin) — dose reduction may be needed. QT-prolonging drug interaction check. Embryo-fetal toxicity — contraception during and 2 weeks post-treatment. Hand-foot syndrome prevention counselling. Hair depigmentation — common and benign; counsel proactively.

 

11. FREQUENTLY ASKED QUESTIONS

Q: Why must I take both tablets at the same time?

Pazopanib needs to be taken once daily as a single dose at the same consistent time each day — ideally on an empty stomach. Splitting the dose across the day is not recommended as it changes the absorption pattern.

Q: Can I take the two tablets at night?

Evening dosing is possible for some patients — particularly if you prefer to take it well after your evening meal (ensuring the stomach is empty). Discuss the best timing for your schedule with your oncologist, keeping in mind the fasting requirement.

Q: Is the liver monitoring the same as for the 200mg tablet?

Yes — the same monitoring schedule (pre-treatment, weeks 3, 5, 7, 9, then monthly) applies regardless of which tablet strength you take. The dose and schedule of liver tests are based on the medicine, not the tablet size.

Customer Feedback


Recently Viewed